Raveena Nagareddy

Ms. Raveena Nagareddy

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
RNRaveena Nagareddy
Raveena Nagareddy
Reju ThomasReju Thomas
Reju Thomas
YJYong Yeon Jeong
Yong Yeon Jeong
Immunotherapy has been investigated for decades, and it has provided promising results in preclinical studies. The most important issue that hinders researchers from advancing to clinical studies is the delivery system for immunotherapy agents, such as antigens, adjuvants and agonists, and the activation of these agents at the tumour site. Polymers are among the most versatile materials for a variety of treatments and diagnostics, and some polymers are reactive to either endogenous or exogenous stimuli. Utilizing this advantage, researchers have been developing novel and effective polymeric nanomaterials that can deliver immunotherapeutic moieties. In this review, we summarized recent works on stimuli-responsive polymeric nanomaterials that deliver antigens, adjuvants and agonists to tumours for immunotherapy purposes.

27 May 2024 in Nanomaterials
Verified
Journal Article
Open access
PDF file
Reju ThomasReju Thomas
Reju Thomas
SKsubin Kim
subin Kim
TTThi-Anh-Thuy Tran
Thi-Anh-Thuy Tran
YKYoung Hee Kim
Young Hee Kim
RNRaveena Nagareddy
Raveena Nagareddy
YJYong Yeon Jeong
Yong Yeon Jeong
Background. The aim of the study was to synthesize liposomal nanoparticles loaded with temozolomide and ferucarbotran (LTF) and to evaluate the theranostic effect of LTF in the glioma model. Methods. We synthesized an LTF that could pass through the Blood Brain Barrier (BBB) and localize in brain tumor tissue with the help of magnet guidance. We examined the chemical characteristics. Cellular uptake and cytotoxicity studies were conducted in vitro. A biodistribution and tumor inhibition study was conduted using an in vivo glioma model. Results. The particle size and surface charge of LTF show 108 nm and −38 mV, respectively. Additionally, the presence of ferucarbotran significantly increased the contrast agent effect of glioma compared to the control group in MR imaging. Magnet-guided LTF significantly reduced the tumor size compared to control and other groups. Furthermore, compared to the control group, our results demonstrate a significant inhibition in brain tumor size and an increase in lifespan. Conclusions. These findings suggest that the LTF with magnetic guidance represents a novel approach to address current obstacles, such as BBB penetration of nanoparticles and drug resistance. Magnet-guided LTF is able to enhance therapeutic efficacy in mouse brain glioma.

Verified
Journal Article
Open access
PDF file
EHEunsol Hwang
Eunsol Hwang
JKJahae Kim
Jahae Kim
JKJi-hye Kim
Ji-hye Kim
RNRaveena Nagareddy
Raveena Nagareddy
YJYong Yeon Jeong
Yong Yeon Jeong
KCKang-Ho Choi
Kang-Ho Choi
Evidence on the therapeutic use of nanoparticles for traumatic brain injury (TBI) remains limited. This study aimed to evaluate the neuroprotective potential of atorvastatin-loaded polyethylene glycol (PEG)-conjugated liposomes (LipoStatin) in a mouse model of repetitive TBI. TBI was induced using five controlled head impacts with a 120 g weight at 12-h intervals. Mice were randomly assigned to Sham, Control (saline-treated), Statin (free atorvastatin), Liposome (empty PEGylated liposomes without atorvastatin), and LipoStatin (atorvastatin-loaded PEGylated liposome) groups. LipoStatin (10 mg/kg/day) was intravenously administered for 5 days post-injury. Neurological function was evaluated using the neurological severity score (NSS), while blood–brain barrier (BBB) integrity and neuroinflammation were assessed on day 5, and cellular apoptosis on day 12. LipoStatin-treated mice exhibited the lowest NSSs. IVIS® imaging indicated significantly attenuated BBB disruption (p < 0.001), and Western blot analysis revealed restored caveolin-1 protein levels (p < 0.01), which are associated with BBB integrity. TNF-α levels were reduced considerably in the LipoStatin group compared to both the Control (p < 0.001) and Statin (p < 0.05) groups. Immunofluorescence showed reduced co-localization of caspase-3 with PDGFR-β and GFAP, indicating decreased pericyte and astrocyte apoptosis. These findings suggest that LipoStatin may confer neuroprotection in TBI by stabilizing BBB integrity, reducing inflammation, and mitigating cell death, supporting its potential as an improved nanocarrier-based therapeutic approach.

23 September 2025 in Biomaterials Science
Verified
Journal Article
Closed access
PDF file
RNRaveena Nagareddy
Raveena Nagareddy
SCSahil Chahal
Sahil Chahal
SVShyam Vasvani
Shyam Vasvani
IPIn-Kyu Park
In-Kyu Park
Reju ThomasReju Thomas
Reju Thomas
YJYong Yeon Jeong
Yong Yeon Jeong
Ferroptosis, a non-apoptotic form of cell death, has shown promise in overcoming resistance to conventional therapies that rely on apoptosis. The combination of ferroptosis inducers with radiation therapy has the potential to improve therapeutic outcomes. However, radiation therapy (RT) alone often requires additional non-toxic radiosensitizers to enhance its efficacy, as the lack of oxygen in hypoxic tumor regions leads to radioresistance. In this study, we synthesized hyaluronic acid and squalene nanoclusters embedded with manganese ferrite nanoparticles to enhance radiosensitization and ferroptosis induction. The CD44 receptor-based targeting of hyaluronic acid and cytoprotective effect of squalene makes the nanocluster biocompatible. The manganese ions (Mn2+) within the ferrite structure enable SHMFs to generate reactive oxygen species upon exposure to ionizing radiation, while the iron ions (Fe2+) promote apoptosis and drive the Fenton reaction to induce ferroptosis. Additionally, SHMFs function as dual imaging contrast agents for T1- and T2-weighted magnetic resonance imaging. Cellular studies supported using the ferroptosis inhibitor ferrostatin-1, confirmed the occurrence of ferroptosis. In vivo experiments using a subcutaneous colon cancer model demonstrated that SHMFs significantly enhanced the efficacy of RT, leading to effective tumor cell death. These findings highlight the potential of SHMFs as a novel approach to combining RT with ferroptosis induction for improved cancer therapy.